Slide 1: Courageous Innovation Q2 2022 Update
CourageousInnovation Q2 2022 Update August2022 NASDAQ:OCGN
Slide 2: Cautionary Note on Forward-Looking Statements
Cautionary Note on Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,
Slide 3: We're Here to Make an Impact Through Courageous Innovation
We’re Here to Make an Impact Through CourageousInnovation 3
Slide 4: Path Forward for COVAXIN (BBV152)
Path Forwardfor COVAXIN™(BBV152) Phase 2/3 immuno-bridging and broadening clinical trial, OCU-002, for COVAXIN™ is currently dosing subjects Positive and compelling COVAXIN™ data published in the Lancet Infectious Diseases and Nature Scientific Reports Pre-commercialization efforts continue in Mexic
Slide 5: Progress with Gene Therapy/Biological Programs (Ophthalmology)
Progress with Gene Therapy/Biological Programs (Ophthalmology) Dosing on track in Phase 1/2 clinical trial studying OCU400 gene therapy for the treatment of retinitis pigmentosa resulting from genetic mutations of NR2E3 and RHO Data and Safety Monitoring Board (DSMB) recommends proceeding to Cohort
Slide 6: Introducing NeoCart, Ocugen's Expansion into Restorative Cell Therapy
Introducing NeoCart®, Ocugen’s Expansion into Restorative Cell Therapy NeoCart® is a phase 3-ready cell therapy platform technology being developed for the repair of full-thickness lesions of the knee cartilage in adults FDA granted RMAT designation to NeoCart®, which helps accelerate the timeline f
Slide 7: Financial Update
Financial Update ocugen.
Slide 8: Financial Update: Statement of Operations and Balance Sheet Data
Financial Update Statement of Operations Three months ended June 30, 2022 2021 Research and development expense $9.0 $18.9 General and administrative expense 10.6 6.8 Other income (expense), net 0.1 (0.3) Net loss $(19.5) $(26.0) Net loss per share of common stock — basic and diluted $(0.09) $(0.13)
Slide 9: Questions & Answers
Questions & Answers ocugen.
Slide 10: Thank you!
August 2022 NASDAQ:OCGN Thankyou!